Advertisement
Commentary Free access | 10.1172/JCI133222
1Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
2IMM-PACT Clinician Scientist Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Address correspondence to: Robert Thimme, University Hospital Freiburg, Department of Medicine II, Hugstter Strasse 55, Freiburg 79106, Germany. Phone: 49.761.270.34030; Email: robert.thimme@uniklinik-freiburg.de.
Find articles by Binder, B. in: JCI | PubMed | Google Scholar
1Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
2IMM-PACT Clinician Scientist Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Address correspondence to: Robert Thimme, University Hospital Freiburg, Department of Medicine II, Hugstter Strasse 55, Freiburg 79106, Germany. Phone: 49.761.270.34030; Email: robert.thimme@uniklinik-freiburg.de.
Find articles by Thimme, R. in: JCI | PubMed | Google Scholar
Published January 6, 2020 - More info
Chronic hepatitis C virus (HCV) infection is characterized by persistent high-level viremia and defective cellular immunity, including a lack of functional HCV-specific CD4+ T cells. We previously described an exceptional period of viral control that occurs in some chronically infected women after childbirth. Here, we investigated whether reduced HCV replication after pregnancy is associated with recovery of CD4+ T cell immunity. Class II tetramer analysis revealed significantly greater frequencies of circulating HCV-specific CD4+ T cells at 3 months postpartum in women with concurrent declines in viremia compared with those with stable viremia. These HCV-specific CD4+ T cells had an effector-memory phenotype. Inhibitory coreceptor expression on these cells corresponded to the degree of viral control. Circulating CD4+ T cells produced IL-2 and IFN-γ after HCV antigen stimulation, demonstrating Th1 functionality. These data provide direct evidence that the profound loss of HCV-specific CD4+ T cell help that results in chronic infection is reversible following pregnancy, and this recovery of CD4+ T cells is associated with at least transient control of persistent viral replication.
Samantha L. Coss, Almudena Torres-Cornejo, Mona R. Prasad, Melissa Moore-Clingenpeel, Arash Grakoui, Georg M. Lauer, Christopher M. Walker, Jonathan R. Honegger
CD4+ T cell failure is a hallmark of chronic hepatitis C virus (HCV) infection. However, the mechanisms underlying the impairment and loss of virus-specific CD4+ T cells in persisting HCV infection remain unclear. Here we examined HCV-specific CD4+ T cells longitudinally during acute infection with different infection outcomes. We found that HCV-specific CD4+ T cells are characterized by expression of a narrower range of T cell inhibitory receptors compared with CD8+ T cells, with initially high expression levels of PD-1 and CTLA-4 that were associated with negative regulation of proliferation in all patients, irrespective of outcome. In addition, HCV-specific CD4+ T cells were phenotypically similar during early resolving and persistent infection and secreted similar levels of cytokines. However, upon viral control, CD4+ T cells quickly downregulated inhibitory receptors and differentiated into long-lived memory cells. In contrast, persisting viremia continued to drive T cell activation and PD-1 and CTLA-4 expression, and blocked T cell differentiation, until the cells quickly disappeared from the circulation. Our data support an important and physiological role for inhibitory receptor–mediated regulation of CD4+ T cells in early HCV infection, irrespective of outcome, with persistent HCV viremia leading to sustained upregulation of PD-1 and CTLA-4.
Diana Y. Chen, David Wolski, Jasneet Aneja, Lyndon Matsubara, Brandon Robilotti, Garrett Hauck, Paulo Sergio Fonseca de Sousa, Sonu Subudhi, Carlos Augusto Fernandes, Ruben C. Hoogeveen, Arthur Y. Kim, Lia Lewis-Ximenez, Georg M. Lauer
Liver disease as a result of chronic hepatitis C virus (HCV) infection is a global problem. While some HCV infections resolve spontaneously, viral persistence associates with compromised T cell immunity. In this issue of the JCI, Chen et al. and Coss et al. explored virus-specific CD4+ T cell response during HCV infection. Both studies evaluated the HCV-specific T cells of patients with different courses of infection. Chen et al. revealed that initial CD4+ T cell responses are similar during early infection and that T cell failure resulted from loss of the virus-specific T cells themselves. Coss et al. showed that HCV-specific CD4+ T cells temporarily recovered in some women following childbirth. These studies contribute to our understanding of CD4+ T cell functionality during different natural courses of infection, with the notable implication that restoring CD4+ T cell immunity might contribute to controlling HCV infection.
Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease, liver cirrhosis, and death worldwide. It is also an excellent model to study the role of virus-specific T cell responses in human viral infection with a dichotomous outcome: viral clearance versus persistence. Indeed, studies in acutely and chronically infected patients have shown that the presence of highly functional and multi-specific CD4+ T cell responses is associated with viral clearance, whereas chronic infection is characterized by only weak and functionally impaired CD4+ T cell responses (1–9). The central role of CD4+ T cells has been further underlined in the chimpanzee model, where antibody-mediated depletion of CD4+ T cells in two immune chimpanzees resulted in persistent, low-level viremia following reinfection (10). However, despite these associations, several important questions have remained open. For example, little is known about the phenotype and fate of the virus-specific CD4+ T cells that are present during acute versus chronic infection. It is also currently unclear whether the weak and impaired CD4+ T cells present during chronic infection can recover when infection is controlled. With the usage of MHC class II tetramers that allow a reliable analysis of virus-specific CD4+ T cells, and with access to unique and longitudinal patient samples, Chen et al. and Coss et al. provide important information regarding these open questions in this issue of the JCI (11, 12).
Chen et al. analyzed the phenotype and function of HCV-specific CD4+ T cells in acutely infected patients who either spontaneously cleared the virus or progressed to chronic infection (11). Interestingly, they found that the virus-specific CD4+ T cells did not differ between the patient groups during the acute infection phase, irrespective of the infection outcome. Indeed, no differences in the frequency, phenotype (including inhibitory molecules), and functionality of virus-specific CD4+ T cell responses were observed. Most cells expressed the inhibitory and activating molecules programmed death 1 (PD-1), cytotoxic T lymphocyte–associated protein 4 (CTLA-4), and CD38, indicating activation (Figure 1A). In agreement with previous studies (13–15), the frequency of the virus-specific CD4+ T cells diminished rapidly in patients who progressed to chronic infection. Accordingly, HCV-specific CD4+ T cell responses were hardly detectable during chronic infection. These results clearly indicate that the absence of vigorous CD4+ T cell responses during chronic infection is not caused by deficient priming, but rather by rapid disappearance of the CD4+ T cells themselves. In subjects who resolved the infection, the frequency of HCV-specific CD4+ T cells remained rather stable. These cells downregulated PD-1, CTLA-4, and CD38, and upregulated the memory marker CD127, thus resembling memory cells (Figure 1A). In contrast, virus-specific CD4+ T cells in patients with ongoing viral replication displayed a higher expression of PD-1 and CTLA-4 but also CD38, indicating continuous activation. These results align with previous studies showing upregulated inhibitory molecules in the chronic phase of infection (16, 17).
Virus-specific CD4+ T cell response during HCV infection. Characterization of virus-specific CD4+ T cells in acute resolving versus persisting HCV infection as displayed by (A) Chen et al. and (B) Coss et al. in the setting of pregnancy-associated viral control.
Coss et al. addressed the important question of whether the immune system can functionally restore these scarce and impaired CD4+ T cells in chronically infected subjects when the virus is controlled (12). One exceptional period of viral control has been previously reported by the Honegger group in some chronically HCV-infected women after childbirth (18, 19). Importantly, by analyzing the virus-specific CD4+ T cell response in this unique cohort, Coss et al. observed a higher frequency of circulating virus-specific CD4+ T cells in women who were 3 months postpartum and had achieved viral control (defined by at least 1 log10 viral load reduction) compared with the same patients in their last trimester and with women with no viral control. The higher number of CD4+ T cells was also reflected by higher frequencies of interferon γ–producing (IFN-γ–producing) and interleukin 2–producing (IL-2–producing) virus-specific cells (Figure 1B). Noteworthy, both correlated with the extent of reduction of viral load. These results indicate a direct role of virus-specific CD4+ T cells in viral control, although the underlying mechanisms have not been addressed (12). However, based on the previous finding by the same group that the drop in viremia after childbirth is accompanied by renewed selection pressure on class I epitopes (18), it is tempting to speculate that CD4+ T cells primarily mediate their antiviral effects by providing help for CD8+ T cell responses.
Importantly, both studies explored the dynamic expression of inhibitory receptors on virus-specific CD4+ T cells (11, 12). First, during acute infection, a high expression of inhibitory receptors such as PD-1 and CTLA-4 is observed irrespective of the outcome of infection, further supporting the concept that these markers not only indicate exhaustion, but also activation. It is noteworthy, however, that an upregulation of PD-1 and CTLA-4 on virus-specific CD4+ T cells was linked to impaired proliferative capacity. Second, the coexpression of inhibitory receptors on CD4+ T cells was significantly less pronounced compared with CD8+ T cell responses (20), indicating a differential regulation of CD4+ versus CD8+ T cells. Thus, restoring these different T cell subsets will likely require different checkpoint inhibitors. Third, in periods of viral control, recovered HCV-specific CD4+ T cells still highly expressed PD-1, but not CTLA-4. These results again suggest that PD-1 is a marker of activation. However, they also agree with previous findings that PD-1 is maintained on virus-specific CD8+ T cells after direct-acting antiviral–mediated (DAA-mediated) HCV elimination (21), indicating a possible chronic signature on T cells that is not simply reversed by antigen reduction. Clearly, further studies are required to address the transcriptional, phenotypical, and functional recovery of virus-specific CD4+ T cells in clinical settings of viral control. One such obvious situation is DAA-mediated elimination, where early immunological studies have failed to show significant changes within the CD4+ compartment (22). In line with this, clinical studies showed a lack of protective immunity from reinfection in subjects who had successfully cleared HCV infection by DAA therapy (23). These results suggest that loss of antigen alone may be insufficient to fully restore CD4+ T cell–mediated immunity, as has also been shown for the CD8+ T cell compartment (24).
Taken together, the two elegant studies by the groups of Honegger and Lauer give several important insights into the central role, fate, and recovery potential of virus-specific CD4+ T cells in the control of HCV infection (11, 12). They also point out the importance of HCV as a unique model to study virus-specific CD4+ T cells in a relevant human infection with a dichotomous outcome and with spontaneous and therapy-mediated episodes of viral control.
RT is supported by the Deutsche Forschungsgemeinschaft German Research Foundation (Transregio Research Center 179 and Collaborative Research Center 1160). BB is funded by the Deutsche Forschungsgemeinschaft and the IMM-PACT Clinician Scientist Programme.
Address correspondence to: Robert Thimme, University Hospital Freiburg, Department of Medicine II, Hugstter Strasse 55, Freiburg 79106, Germany. Phone: 49.761.270.34030; Email: robert.thimme@uniklinik-freiburg.de.
Conflict of interest: The authors have declared that no conflict of interest exists.
Copyright: © 2020, American Society for Clinical Investigation.
Reference information: J Clin Invest. 2020;130(2):595–597. https://doi.org/10.1172/JCI133222.
See the related article at Hepatitis C virus–specific CD4+ T cell phenotype and function in different infection outcomes.
See the related article at CD4+ T cell restoration and control of hepatitis C virus replication after childbirth.